Cointime

ImmunoMet Therapeutics

company

About

ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients.

  • 1 - 10

Highlights

Total Funding Amount
$12M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$5M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$12M
ImmunoMet Therapeutics has raised a total of $12M in funding over 2 rounds. Their latest funding was raised on Feb 8, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 8, 2021 Series Unknown $7M 1 — — Detail
Mar 7, 2017 Series B $5M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
ImmunoMet Therapeutics is funded by 1 investors. SL Investment are the most recent investors.
Investor Name Lead Investor Funding Round
SL Investment — Series Unknown
Cointime
เนื้อหา
บริษัท